(Q36713493)

English

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

scientific article published on 3 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study (English)

1 reference

Europe PubMed Central

15 August 2017

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Stephen P Hunger

3

object named as

Stephen P Hunger

1 reference

Europe PubMed Central

15 August 2017

Cheryl L. Willman

11

object named as

Cheryl L Willman

1 reference

Europe PubMed Central

15 August 2017

author name string

Michael J Borowitz

1

1 reference

Europe PubMed Central

15 August 2017

Meenakshi Devidas

2

1 reference

Europe PubMed Central

15 August 2017

W Paul Bowman

4

1 reference

Europe PubMed Central

15 August 2017

Andrew J Carroll

5

1 reference

Europe PubMed Central

15 August 2017

William L Carroll

6

1 reference

Europe PubMed Central

15 August 2017

Stephen Linda

7

1 reference

Europe PubMed Central

15 August 2017

Paul L Martin

8

1 reference

Europe PubMed Central

15 August 2017

D Jeanette Pullen

9

1 reference

Europe PubMed Central

15 August 2017

David Viswanatha

10

1 reference

Europe PubMed Central

15 August 2017

Naomi Winick

12

1 reference

Europe PubMed Central

15 August 2017

Bruce M Camitta

13

1 reference

Europe PubMed Central

15 August 2017

Children's Oncology Group

14

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

3 April 2008

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

111

1 reference

Europe PubMed Central

15 August 2017

5477-5485

1 reference

Europe PubMed Central

15 August 2017

12

1 reference

Europe PubMed Central

15 August 2017

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Minimal residual disease as a surrogate marker for risk assignment to ALL patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Flow Cytometric Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Immunologic monitoring in adults with acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: inv

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

The use of flow cytometry to detect minimal residual disease in acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

30 September 2017

Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

28 June 2018

Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report fr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

28 June 2018

Detection and quantitation of neoplastic cells in acute lymphoblastic leukaemia, by use of the polymerase chain reaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

28 June 2018

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2424148

5 September 2018

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reavtion identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR

1 reference

https://pubmed.ncbi.nlm.nih.gov/18388178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-01-132837

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36713493&oldid=1647207626"